Alexion’s rare blood disorder drug ‘succeeds’
By Reuters
March 16, 2018
WASHINGTON: Alexion Pharmaceuticals Inc said on Thursday its experimental drug to treat patients with a rare blood disorder met the main goal in a late-stage study, sending its shares up 18 percent in premarket trading.
The drug, ALXN1210, was being tested against the company’s flagship drug, Soliris, in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). The company said the drug demonstrated non-inferiority to Soliris on the main goal as well as four of the key secondary goals. Alexion said it expects to file marketing application for the drug in the United States, the European Union and Japan in the second half of 2018.
-
Pentagon Threatens To Cut Ties With Anthropic Over AI Safeguards Dispute -
Meghan Markle's Father Shares Fresh Health Update -
Travis Kelce Takes Hilarious Jab At Taylor Swift In Valentine’s Day Post -
NASA Confirms Arrival Of SpaceX Crew-12 Astronauts At The International Space Station -
Can AI Bully Humans? Bot Publicly Criticises Engineer After Code Rejection -
Search For Savannah Guthrie’s Abducted Mom Enters Unthinkable Phase -
Imagine Dragons Star, Dan Reynolds Recalls 'frustrating' Diagnosis -
Steve Jobs Once Called Google Over Single Shade Of Yellow: Here’s Why -
Barack Obama Addresses UFO Mystery: Aliens Are ‘real’ But Debunks Area 51 Conspiracy Theories -
Selma Blair Explains Why Multiple Sclerosis 'isn't So Scary' -
Will Smith Surprises Wife Jada Pinkett With Unusual Gift On Valentine's Day -
Shamed Andrew Has Paid Royal Favours With ‘national Scandal’ -
Prince William Ticked Off By How Andrew ‘behaved With Staff’ -
Prince William Questions Himself ‘what’s The Point’ After Saudi Trip -
James Van Der Beek's Friends Helped Fund Ranch Purchase Before His Death At 48 -
King Charles ‘very Much’ Wants Andrew To Testify At US Congress